Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Review

Accepted on 27 Jun 2025

CRISPR/Cas9 Technology in Tumor Research and Drug Development Application Progress and Future Prospects

in Pharmacology of Anti-Cancer Drugs

Weiqiang Zhou
Han Han
Xiaoyan Sun
Xiaoyun Guo
Jiaxin Wen
Xiaoming Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1552741

243 views

Original Research

Published on 27 Jun 2025

Glycyrrhiza uralensis Fisch. suppresses cell migration via ROS and JAK/STAT signalling pathways in Drosophila

in Pharmacology of Anti-Cancer Drugs

Fangfei Zhou
Qingge Lu
Lingyu Kong
Sitong Wang
Haixia Zhang
Meng Zhao
Yue Hu
Fanwu Wu
Chenxi Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1549920

306 views

Original Research

Published on 26 Jun 2025

Galectin-9 treatment is cytotoxic for B cell lymphoma by disrupting autophagy

in Pharmacology of Anti-Cancer Drugs

Lisanne Koll
Harm Jan Lourens
Glenn Marsman
Stan de Haan
Toshiro Niki
Gerwin A. Huls
Edwin Bremer
Valerie R. Wiersma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1601235

416 views

Original Research

Accepted on 25 Jun 2025

BCL6 Promotes the Progression of High-Grade Serous Ovarian Cancer Cells by Inhibiting PLAAT4

in Pharmacology of Anti-Cancer Drugs

An Wan
Wei-Dong Zhao
Gang Chen
Cheng Peng
Jinhui Tao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1634995

104 views

Original Research

Accepted on 25 Jun 2025

Synergistic Anticancer Effects of Camptothecin and Sotorasib in KRAS-Mutated Pancreatic Ductal Adenocarcinoma

in Pharmacology of Anti-Cancer Drugs

Prasanna Srinivasan Ramalingam
Gayathri Chellasamy
Md Sadique Hussain
Kodiveri Muthukaliannan Gothandam
Tajamul Hussain
SALMAN ALROKAYAN
Kyusik Yun
Janaki Ramaiah Mekala
Sivakumar Arumugam

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1635449

166 views

Original Research

Accepted on 25 Jun 2025

Dihydroartemisinin Targets the miR-497-5p/SOX5 Axis to Suppress Tumor Progression in Non-Small Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

Qinghua Yin
Qiang Zhou
Jian-Bing Hu
Jie Weng
Er-Dong Shen
Fang Wen
Song-Lian Liu
Lei- Lan Yin
Ya-Jun Tong
Ling Long

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1605531

159 views

Case Report

Accepted on 25 Jun 2025

Spermatocytic Tumor Associated With Metastases: Report of a Rare Case and Literature Review

in Pharmacology of Anti-Cancer Drugs

Jianbai Chen
Xiaorong Mou
Zhiming Zhang
Wei Zhang
Zhiyong Nie
Xiaoping Gao
Yanyao Gao
Jianxin Qiu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1636142

Review

Accepted on 25 Jun 2025

MicroRNA-145 in Urologic Tumors: Biological Roles, Regulatory Networks, and Clinical Translation

in Pharmacology of Anti-Cancer Drugs

Lifeng Gan
Wei Li
琪陈
乐程
Fangtao Zhang
Haidong Zhong
Yiran Lu
Biao Qian
Liying Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1609646

Review

Accepted on 24 Jun 2025

Multi-omics Dissection of Tumor Microenvironment-Mediated Drug Resistance: Mechanisms and Therapeutic Reprogramming

in Pharmacology of Anti-Cancer Drugs

Chen Fanghua
Fu Yuandong
Bai Gaigai
Qiu Junjun
Keqin Hua

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1634413

115 views

Methods

Accepted on 24 Jun 2025

HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective Phase Ib/II trial

in Pharmacology of Anti-Cancer Drugs

Qingqing Leng
Jitao Zhou
Xin Wang
Huanji Xu
Pei Zhang
Dan Cao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1562481

171 views

Review

Accepted on 24 Jun 2025

Review projecting shikonin as a therapeutic candidate in female carcinomas: A preclinical perspective

in Pharmacology of Anti-Cancer Drugs

Pratibha Pandey
Sorabh Lakhanpal
Jamuna K. V.
Ajay Singh
Mohammad Abohassan
Moon Nyeo Park
Sang-Won Shin
Han Na Kang
Manaal Zahera
Mohd Saeed

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1627124

110 views

Original Research

Published on 24 Jun 2025

Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess

in Pharmacology of Anti-Cancer Drugs

Weimin Gao
Zhigang Xia
Tingfeng Zhou
Youlin Dong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1602276

349 views

Original Research

Published on 24 Jun 2025

CircASH1L inhibits ferroptosis and enhances cisplatin resistance by sponging miR-515-5p to regulate cell cycle-related CDCA7/RRM2 in ovarian cancer cells

in Pharmacology of Anti-Cancer Drugs

Lu Feng
Xinru Zou
Longyu Tang
Yijun Yuan
Tianwen He
Bin Su
Ying Tang
Jiang Wang
Kang Liu
Jun Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1563869

312 views

Original Research

Accepted on 23 Jun 2025

Independent Risk and Protective Factors for Oxaliplatin-Induced Hypersensitivity Reactions: A Retrospective Study

in Pharmacology of Anti-Cancer Drugs

Jing Xue
Zhihao Lian
Xiaoyan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1624322

123 views

Original Research

Accepted on 23 Jun 2025

EGCG and DOX dual-drug-loaded enzyme-responsive nanovesicles boost mitochondrial-mediated ICD for improved immunotherapy

in Pharmacology of Anti-Cancer Drugs

Mengxue Zhou
Ying Wang
Hongchun Cui
Huan Geng
Lifu Ruan
Yanni Zhao
Chuang Zhou
Weidong Dai
Jun Chen
Jizhong Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1624109

170 views

Original Research

Accepted on 23 Jun 2025

Aloe-emodin mediates the inhibitory effect of LncRNA D63785 on the PI3K/Akt/mTOR pathway in nasopharyngeal carcinoma

in Pharmacology of Anti-Cancer Drugs

Min He
Lei Xie
Jiayi Huang
Han Su
Jiahua Hu
Liuping Xie
Mengqin Li
Xin Zeng
Jianhong Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1573408